Get the Stockscreener App
3.17
0.32%
0.010
Atea Pharmaceuticals Inc stock is traded at $3.17, with a volume of 15,180.
It is up +0.32% in the last 24 hours and down -11.70% over the past month.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
See More
Previous Close:
$3.16
Open:
$3.17
24h Volume:
15,180
Relative Volume:
0.08
Market Cap:
$266.90M
Revenue:
$351.37M
Net Income/Loss:
$-135.96M
P/E Ratio:
-2.4766
EPS:
-1.28
Net Cash Flow:
$-85.40M
1W Performance:
-4.23%
1M Performance:
-11.70%
6M Performance:
-12.19%
1Y Performance:
+10.45%
1-Day Range:
$3.155
$3.205
1-Week Range:
$3.095
$3.35
52-Week Range:
$2.765
$4.60
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Name
Atea Pharmaceuticals Inc
Sector
Industry
Phone
857-204-8109
Address
225 FRANKLIN STREET, BOSTON
Compare AVIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| AVIR | 3.18 | 266.90M | 351.37M | -135.96M | -85.40M | -1.28 |
| VRTX | 445.32 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 736.78 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 584.00 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.00 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.17 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-10-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-18-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-25-20 | Initiated | Evercore ISI | Outperform |
| Nov-24-20 | Initiated | JP Morgan | Overweight |
| Nov-24-20 | Initiated | Morgan Stanley | Overweight |
| Nov-24-20 | Initiated | William Blair | Outperform |
View All
Atea Pharmaceuticals Inc Stock (AVIR) Latest News
Atea Pharmaceuticals Presents Multiple New Datasets - GlobeNewswire
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024 - GlobeNewswire Inc.
FMR LLC Increases Stake in Atea Pharmaceuticals Inc - GuruFocus.com
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is BML Capital Management LLC's 3rd Largest Position - MarketBeat
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2024 Earnings Call Transcript - Insider Monkey
Atea Pharmaceuticals Advances in HCV Treatment Development - TipRanks
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Atea Reports $31.2M Loss, Exits COVID Program Despite Strong HCV Pipeline Results | AVIR Stock News - StockTitan
AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Thursday - MarketBeat
Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 - The Manila Times
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 - The Manila Times
Atea Pharmaceuticals to Present New Data Supporting the - GlobeNewswire
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024 - StockTitan
SG Americas Securities LLC Increases Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Respiratory Syncytial Virus Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | GSK, MedImmune, ReViral, Pfizer, Sanofi, BioComo, Merck - The Globe and Mail
Morgan Stanley Upgrades Atea Pharmaceuticals (AVIR) - MSN
Atea Pharmaceuticals Leads The Charge In US Penny Stocks Spotlight - Simply Wall St
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance
Dimensional Fund Advisors LP Buys 211,428 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
182,326 Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Purchased by Marshall Wace LLP - MarketBeat
Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Almitas Capital LLC Invests $4.27 Million in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Metrics That Matter About Atea Pharmaceuticals Inc (NASDAQ: AVIR) - Stocks Register
Jean-Pierre Sommadossi Sells 33,941 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stock - MarketBeat
Atea Pharmaceuticals CEO sells over $234k in company stock - Investing.com India
Atea Pharmaceuticals CEO sells over $234k in company stock By Investing.com - Investing.com UK
Q3 2024 EPS Estimates for Atea Pharmaceuticals, Inc. Lifted by Analyst (NASDAQ:AVIR) - MarketBeat
Data from Merck, Daiichi could support first approval for HER3 ADC - BioCentury
Atea Pharmaceuticals (NASDAQ:AVIR) & SELLAS Life Sciences Group (NASDAQ:SLS) Critical Analysis - Defense World
Short Interest in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Rises By 13.7% - MarketBeat
Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus - AOL
AVIR’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
Atea Pharmaceuticals Shares Fall on Covid-19 Treatment Trial Result - MarketWatch
Atea stock drops as COVID-19 therapy fails in late-stage trial - MSN
Atea stock falls after setback to COVID-19 drug (NASDAQ:AVIR) - Seeking Alpha
Atea Pharmaceuticals reports Phase 3 trial miss for COVID-19 drug - Investing.com
Atea Pharmaceuticals Trial of Covid-19 Treatment Bemnifosbuvir Fails to Meet Primary Endpoint - MarketWatch
Atea Pharmaceuticals Provides Update on Global Phase 3 - GlobeNewswire
Atea Pharmaceuticals Provides Update on Global Phase 3 Rise-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19 - Marketscreener.com
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Acadian Asset Management LLC - Defense World
New Data on Bemnifosbuvir's Progress in COVID-19 and HCV Trials - Contagionlive.com
Atea Pharmaceuticals advances antiviral drug study - Investing.com
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by SG Americas Securities LLC - Defense World
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway - ForexTV.com
Atea Pharmaceuticals Announces Publication of Additional - GlobeNewswire
California State Teachers Retirement System Cuts Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals Inc Stock (AVIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atea Pharmaceuticals Inc Stock (AVIR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sommadossi Jean-Pierre | President, CEO, and Chairman |
Sep 18 '24 |
Sale |
4.03 |
22,187 |
89,469 |
5,867,866 |
| Sommadossi Jean-Pierre | President, CEO, and Chairman |
Sep 19 '24 |
Sale |
4.00 |
1,841 |
7,367 |
5,866,025 |
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):